- $183.74m
- $174.37m
- $32.38m
Stereotaxis rises after FDA clears new heart-procedure platform
Surgical robotics firm Stereotaxis Q4 revenue jumps
Brief: Stereotaxis Q4 Revenue USD 8.642 Million
Brief: Stereotaxis Receives FDA Approval For Magic Ablation Catheter
Brief: Stereotaxis Q3 Revenue USD 7.464 Million
Brief: Stereotaxis Enters Sales Agreement Of $50 Million Common Stock With Roth Capital
Brief: Stereotaxis Receives U.S. FDA Clearance For Magic Sweep Catheter
Brief: Stereotaxis Inc Files For Resale Of Up To 6.1 Mln Common Shares
Brief: Stereotaxis Receives CE Mark Recertification Under EU’S MDR Regulatory Framework
Brief: Stereotaxis Reports 2023 Full Year Financial Results
Brief: Stereotaxis To Initiate First-In-Human Trial To Support CE Mark Application Of Magic Catheter
Brief: Stereotaxis Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: Stereotaxis Inc Files Prospectus For Resale Of Up To 91.2 Million Shares Of Co's Common Stock By Selling Stockholders - SEC Filing
U.S. STOCKS ON THE MOVE-Stereotaxis, AbbVie, CureVac
Stereotaxis rises on partnership with Abbott on medical robotic
Brief: Stereotaxis And Abbott Announce Global Collaboration Combining Leading Mapping And Robotic Technologies To Improve Treatment Of Abnormal Heart Rhythms
Brief: Stereotaxis Reports 2023 First Quarter Financial Results
Brief: Stereotaxis Reports 2022 Full Year Financial Results
Brief: Stereotaxis Reports Third Quarter Financial Results